Personalized precision medicine powered by AI for cancer therapy
Stage
Not given
Not given
Founded
Not given
Not given
Based in
DE
US
Pricing model
Paid
Contact for pricing
Pricing
Single Snapshot: $19 for one blood test analysis. Progress Tracker: $89 for 6 comprehensive reports. Annual Health Guardian: $159 for 12 detailed reports. Add-on reports for Annual Guardian users: $9 each.
Not given
Key features
AI-assisted analysis of blood test results with extraction of all biomarkers and values
Plain-language explanations of each biomarker and health significance
Personalized optimal ranges based on age, gender, and health profile
Trend visualization and comparative timeline analysis across multiple tests
Actionable evidence-based lifestyle and nutrition recommendations
Doctor-ready PDF reports for sharing with healthcare providers
Secure encrypted data protection with no server storage after analysis
Support for common blood test formats including PDF and image files
Analyzes digital pathology with no additional tissue staining required
Rapid results within 1-2 days after specimen receipt
Validated across diverse populations including African American and non-African American men
FDA De Novo authorization for prostate cancer risk stratification
Insurance coverage for Medicare and many commercial plans
Provides 5 and 10-year distant metastasis risk for breast cancer
Identifies breast cancer patients who benefit from chemotherapy
Included in NCCN Clinical Practice Guidelines for Prostate Cancer
What makes it different
Personalized analysis that adds context based on your individual profile instead of one-size-fits-all normal ranges
Longitudinal trend tracking across multiple tests to identify long-term health patterns and changes
Clear preparation for doctor conversations with comprehensive summaries before appointments
Access to hundreds of blood biomarkers with AI-powered science-backed interpretation
No additional tissue preparation needed, uses existing H&E slides
Validated across multiple large randomized phase III clinical trials
FDA De Novo clearance as Software as a Medical Device
Financial assistance program to make tests affordable regardless of income
BLDscan
ArteraAI